Funding for this research was provided by:
Prestige Bio Pharma ltd, Singapore
Received: 30 September 2022
Accepted: 23 January 2023
First Online: 31 January 2023
: TROIKA trial (NCT03013504) that was reported according to the Enhancing the Quality and Transparency Of Health Research guidelines. The TROIKA trial was conducted according to the ethical principles of good clinical practice and was approved by ethics committees in each involved country. All patients signed an informed consent to participate in the trial which are available at request submitted to Prestige Bio Pharma, (2 Science Park Dr, #04–13/14 Ascent Tower B, Singapore Science Park, Singapore 118222). An independent monitoring committee monitored the study.List of the ethics committees / institutional review board that approved the study.Table removedTable removedTable removedTable removedTable removedTable removedTable removedTable removed
: Not applicable.
: Conflict of Interest Disclosures: Dr. Pivot reported being an unpaid adviser for Prestige Biopharma. Dr Dzagnidze reported personal fees from Khechinashvili University Hospital during the conduct of the study. Dr Kaewkangsadan reported grants from Prestige BioPharma during the conduct of the study. Drs Derde, Kaufman, and Deforce are/were employees of DICE Ltd. and had a memorandum of understanding with Prestige BioPharma Ltd. No other disclosures were reported.